What Does ECOG Performance Status Mean?

Somewhere in your oncology note there is a line like "ECOG 1." It is one digit. It often decides more than the digits you were watching, such as tumor size.

ECOG stands for Eastern Cooperative Oncology Group, the research network that wrote the scale. The scale does not measure your cancer. It measures how much of your ordinary day the cancer and its treatment have taken.

The SEER Training Modules, published by the National Cancer Institute, give the wording used across oncology:

• 0 — "Fully active, able to carry on all pre-disease performance without restriction"
• 1 — "Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature"
• 2 — "Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours"
• 3 — "Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours"
• 4 — "Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair"
• 5 — "Dead"

Grade 5 exists because the scale was built for research datasets, which have to record every outcome. You will not see it in a clinic note about a living patient.

Read grades 2 and 3 again. Both hang on one measurable thing: the share of your waking hours you spend up and about versus in a bed or chair.

That is unusually concrete for a clinical scale, and it is worth using. If you are awake 14 hours and spend 8 of them sitting in a recliner because of fatigue, you are on the 3 side of that line, whatever anyone assumed at the last visit.

Notice what the scale does not ask about. Not pain scores. Not appetite. Not mood. Not how bad your scan looked. Someone with severe pain that is well controlled can be a 1. Someone with a small tumor who cannot get off the couch is not.

Performance status is used as a gate, and it is used as a forecast.

As a gate, it appears in the entry rules for clinical trials and in the selection of aggressive regimens. The National Cancer Institute's summary of renal cell cancer treatment describes the patients most likely to benefit from cytokine therapy as those who "have nonbulky pulmonary or soft tissue metastases with excellent performance status ratings of 0 or 1, according to the Eastern Cooperative Oncology Group (ECOG) rating scale, and the patients show no weight loss."

As a forecast, it carries independent weight. NCI's summary of non-small cell lung cancer treatment states that for patients with inoperable disease, "prognosis is adversely affected by poor performance status and weight loss of more than 10%," and notes that such patients have generally been left out of trials of aggressive combined treatment.

Read those two sentences together and you can see the loop clinicians worry about. People who function poorly are excluded from the trials, so less is known about treating them, so fewer options get built for them.

You may also see a percentage instead of a digit. That is the Karnofsky scale, developed in the 1940s. SEER Training Modules list all eleven steps:

100% is "normal health." 90% is "minor symptoms." 80% is "normal activity with some effort." 70% is "unable to carry on normal activity but able to care for oneself." 60% is "requires occasional help with personal needs." 50% is "requires considerable assistance and medical care." 40% is "disabled." 30% is "severely disabled, in hospital." 20% is "very sick, active support needed." 10% is "moribund (near death)." 0% is death.

The practical difference is resolution. Karnofsky has eleven steps; ECOG has six. A real decline can show up as a Karnofsky drop from 80% to 70% while the ECOG number does not move at all. If your team uses both, ask which one their trial or protocol actually requires.

Also worth knowing: SEER notes this data "is not collected by oncology data specialists for cancer surveillance." Your performance status lives in the clinical chart, not in the cancer registry. If you change hospitals, the new team will re-score you from scratch.

The score is usually assigned in a few seconds by whoever is typing the note, based on how you look in the room. Three things skew it.

The waiting room effect. You showered, dressed, and drove in. That is your best hour of the week, and it is the hour being scored.

Averaging over a bad cycle. Days 3 through 7 after chemotherapy can look nothing like day 18. A single number cannot hold both.

Nobody asked. The scale is about your hours and your self-care. You are the only person with that data.

You can fix this in about a minute of prep.

Before the visit, count. On a typical day this past week, how many waking hours were you up and moving, and how many were you in a bed or recliner? Note the worst three days and the best three days separately. Note what you stopped doing that you were doing a month ago, in plain terms: stairs, driving, cooking, showering without sitting down.

Then say it out loud. "Last week I was in the recliner about nine of fourteen waking hours on most days." That single sentence is more useful than any adjective, and it is exactly the input the scale is built from.

If your number is being used to rule you out of something, ask whether it can be re-scored after a specific fix. Anemia, uncontrolled pain, poorly treated nausea, low thyroid, and deconditioning can all push a score down and can all be treated. A referral to physical therapy or palliative care sometimes moves a 2 back to a 1.

What ECOG number is in my chart today, and what date was it scored? What did you base it on? Which decision is this number gating: a trial, a drug, a dose, or surgery? If it improved by one point, what would open up? Is there a treatable reason it is where it is? Who re-scores it, and when?

See also Cancer Staging, Pathology Reports, and Getting a Second Opinion.

• https://training.seer.cancer.gov/followup/dataset/ecog-performance-status.html
• https://www.training.seer.cancer.gov/followup/dataset/karnofsky-scale.html
• https://www.cancer.gov/types/kidney/hp/kidney-treatment-pdq
• https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq